Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial

Antiviral Research

Volumn 96, Issue 1, 2012, Pages 32-35

  Watanabe, Satoru ^a   Rathore, Abhay P S ^a   Sung, Cynthia ^a   Lu, Fan ^b   Khoo, Yok Moi ^b   Connolly, John ^c   Low, Jenny ^d   Ooi, Eng Eong ^a   Lee, How Sung ^b   Vasudevan, Subhash G ^a  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c AGENCY FOR SCIENCE   (Singapore)

^d SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

AG129 lethal infection mouse model; Antiviral; Dengue virus; Pharmacokinetics

Indexed keywords

CASTANOSPERMINE; CASTANOSPERMINE 6 BUTYRATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DENGUE; DRUG METABOLISM; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEADY STATE; SURVIVAL; THERAPY EFFECT; VIRUS ENVELOPE;

ANIMALS; ANTIVIRAL AGENTS; DENGUE; DENGUE VIRUS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY; INDOLIZINES; MICE; SURVIVAL ANALYSIS;

DENGUE VIRUS; MUS;

EID: 84864925701     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.07.008     Document Type: Article

References (23)

1. Ahmed S.P., Nash R.J., Bridges C.G., Taylor D.L., Kang M.S., Porter E.A., Tyms A.S. Antiviral activity and metabolism of the castanospermine derivative MDL 28,574, in cells infected with herpes simplex virus type 2. Biochem. Biophys. Res. Commun. 1995, 208:267-273.
2. Block T.M., Lu X., Platt F.M., Foster G.R., Gerlich W.H., Blumberg B.S., Dwek R.A. Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:2235-2239.
3. Bridges C.G., Ahmed S.P., Kang M.S., Nash R.J., Porter E.A., Tyms A.S. The effect of oral treatment with 6-O-butanoyl castanospermine (MDL 28,574) in the murine zosteriform model of HSV-1 infection. Glycobiology 1995, 5:249-253.
4. Courageot M.P., Frenkiel M.P., Dos Santos C.D., Deubel V., Despres P. Alpha-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum. J. Virol. 2000, 74:564-572.
5. Durantel D. Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection. Curr. Opin. Invest. Drugs 2009, 10:860-870.
6. Gubler D.J. Dengue/dengue haemorrhagic fever: history and current status. Novartis Found Symp. 2006, 277:3-16. discussion 16-22, 71-13, 251-253.
7. Halstead S.B. Neutralization and antibody-dependent enhancement of dengue viruses. Adv. Virus Res. 2003, 60:421-467.
8. Halstead S.B. Dengue. Lancet 2007, 370:1644-1652.
9. Kang M.S. Uptake and metabolism of BuCast: a glycoprotein processing inhibitor and a potential anti-HIV drug. Glycobiology 1996, 6:209-216.
10. Molyneux R.J., Roitman J.N., Dunnheim G., Szumilo T., Elbein A.D. 6-Epicastanospermine, a novel indolizidine alkaloid that inhibits alpha-glucosidase. Arch. Biochem. Biophys. 1986, 251:450-457.
11. Rathore A.P., Paradkar P.N., Watanabe S., Tan K.H., Sung C., Connolly J.E., Low J., Ooi E.E., Vasudevan S.G. Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model. Antiviral Res. 2011, 92:453-460.
12. Roth H., McPherson M., Hamedani P., Herrmann W.M., Sidarous E., Frampton M., Maddern J., Dieterich A. Phase I tolerance and pharmacokinetics of a new castanospermine derivative, MDL 28,574A. Int. Conf. AIDS 1996, 11:2117.
13. Ruprecht R.M., Bernard L.D., Bronson R., Gama Sosa M.A., Mullaney S. Castanospermine vs. its 6-O-butanoyl analog: a comparison of toxicity and antiviral activity in vitro and in vivo. J. Acquir. Immune Defic. Syndr. 1991, 4:48-55.
14. Saito T., Yamaguchi I. Effect of glycosylation and glucose trimming inhibitors on the influenza A virus glycoproteins. J. Vet. Med. Sci. 2000, 62:575-581.
15. Schlesinger S., Koyama A.H., Malfer C., Gee S.L., Schlesinger M.J. The effects of inhibitors of glucosidase I on the formation of Sindbis virus. Virus Res. 1985, 2:139-149.
16. Schul W., Liu W., Xu H.Y., Flamand M., Vasudevan S.G. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J. Infect. Dis. 2007, 195:665-674.
17. Sorbera L.A., Castañer J., García-Capdevila L. Celgosivir. Drugs Future 2005, 30:545-552.
18. Sunkara P.S., Taylor D.L., Kang M.S., Bowlin T.L., Liu P.S., Tyms A.S., Sjoerdsma A. Anti-HIV activity of castanospermine analogues. Lancet 1989, 1:1206.
19. Taylor D.L., Fellows L.E., Farrar G.H., Nash R.J., Taylor-Robinson D., Mobberley M.A., Ryder T.A., Jeffries D.J., Tyms A.S. Loss of cytomegalovirus infectivity after treatment with castanospermine or related plant alkaloids correlates with aberrant glycoprotein synthesis. Antiviral Res. 1988, 10:11-26.
20. Taylor D.L., Sunkara P.S., Liu P.S., Kang M.S., Bowlin T.L., Tyms A.S. 6-0-butanoylcastanospermine (MDL 28,574) inhibits glycoprotein processing and the growth of HIVs. AIDS 1991, 5:693-698.
21. Whitby K., Pierson T.C., Geiss B., Lane K., Engle M., Zhou Y., Doms R.W., Diamond M.S. Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. J. Virol. 2005, 79:8698-8706.
22. Zellweger R.M., Prestwood T.R., Shresta S. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 2010, 7:128-139.
23. Zitzmann N., Mehta A.S., Carrouee S., Butters T.D., Platt F.M., McCauley J., Blumberg B.S., Dwek R.A., Block T.M. Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:11878-11882.